STOCKHOLM, Nov. 3, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)
("Calliditas") today announced upcoming presentations concerning
Nefecon, its lead product candidate, at the American Society of
Nephrology (ASN) annual Kidney Week 2021 conference, which will be
held virtually November 2-7,
2021.
Both posters will be presented at the `Glomerular Diseases:
Immunology and Inflammation in IgANP, C3GP, TMA, and Nephrotic
Diseases' session, which will take place on November 4 between 10:00am
and 12:00pm (PDT).
Dr Karen Molyneux from the Mayer
IgA Nephropathy Laboratory at the University of Leicester will
present a poster titled "Targeted Release Formulation Budesonide
(Nefecon) Selectively Reduces Circulating Levels of Chemokines
Critical to Immune Cell Trafficking to Peyer Patches in IgA
Nephropathy". In addition, Laura Pérez-Alós will present a poster
titled "Treatment with Targeted Release Formulation Budesonide
(Nefecon) Modulates the Complement System in Patients with IgA
Nephropathy".
"We are delighted that these posters have been selected for the
upcoming ASN Digital Kidney Week 2021 and congratulate the authors.
The results presented in these posters build on the existing body
of biomarker data, and provide additional evidence supporting the
effect of Nefecon on the underlying pathophysiology of IgA
nephropathy," said CMO Richard Philipson.
More details on this session, including on the two posters
described above, can be found here:
https://www.asn-online.org/education/kidneyweek/2021/program-session-details.aspx?sessId=404846
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on November 3, 2021 at 8:00
a.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of adults with the autoimmune
renal disease primary IgA nephropathy (IgAN), for which there is a
high unmet medical need and there are no approved treatments.
Calliditas read out topline data from Part A of its global Phase 3
study in IgAN in November 2020 and,
if approved, aims to commercialize Nefecon in the United States. Calliditas is also planning
to start clinical trials with NOX inhibitors in primary biliary
cholangitis and head and neck cancer. Calliditas is listed on
Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select
Market (ticker: CALT).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Calliditas' strategy, business plans, regulatory
submissions and focus. The words "may," "will," "could," "would,"
"should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "project," "potential," "continue," "target"
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, any related to Calliditas' business, operations, the
potential for FDA acceptance for and the success and timeline of
the development of Nefecon, clinical trials, supply chain,
strategy, goals and anticipated timelines, competition from other
biopharmaceutical companies, and other risks identified in the
section entitled "Risk Factors" in Calliditas' reports filed with
the Securities and Exchange Commission. Calliditas cautions you not
to place undue reliance on any forward-looking statements, which
speak only as of the date they are made. Calliditas disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent Calliditas' views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/calliditas-announces-poster-presentations-at-asn-digital-kidney-week-2021,c3445845
The following files are available for download:
|
https://mb.cision.com/Main/16574/3445845/1490502.pdf
|
ASN Kidney Week PR
ENG
|